12月24日，百利天恒盘中下跌2.00%，截至14:14，报342.40元/股，成交1.57亿元，换手率0.44%，总市 值1413.68亿元。 截至9月30日，百利天恒股东户数5979.00，较上期增加25.08%；人均流通股17208股，较上期减少 20.05%。2025年1月-9月，百利天恒实现营业收入20.66亿元，同比减少63.52%；归母净利润-4.95亿元， 同比减少112.16%。 机构持仓方面，截止2025年9月30日，百利天恒十大流通股东中，中欧医疗健康混合A（003095）位居 第三大流通股东，持股370.19万股，相比上期减少57.78万股。香港中央结算有限公司位居第四大流通股 东，持股289.57万股，相比上期减少69.64万股。华夏上证科创板50成份ETF（588000）位居第五大流通 股东，持股283.37万股，相比上期减少159.13万股。易方达上证科创板50ETF（588080）位居第六大流 通股东，持股229.92万股，相比上期减少101.89万股。永赢医药创新智选混合发起A（015915）位居第 七大流通股东，持股164.98万股，为新进股东。汇添富创新医药混合A（006 ...

12月24日，向日葵盘中上涨2.26%，截至14:02，报7.23元/股，成交2.33亿元，换手率2.55%，总市值 93.07亿元。 资金流向方面，主力资金净流入1228.74万元，特大单买入2477.56万元，占比10.62%，卖出693.29万 元，占比2.97%；大单买入5170.64万元，占比22.16%，卖出5726.17万元，占比24.54%。 资料显示，浙江向日葵大健康科技股份有限公司位于浙江省绍兴袍江工业区三江路，成立日期2005年3 月21日，上市日期2010年8月27日，公司主营业务涉及聚焦医药领域,主要为抗感染类、心血管类、消化 系统类等药物的研发、生产和销售.。主营业务收入构成为：原料类产品73.44%，制剂药产品26.37%， 其他(非主营)0.19%。 向日葵所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：高血压防治、幽门螺杆概 念、原料药、生物医药、小盘等。 截至9月30日，向日葵股东户数13.30万，较上期增加112.98%；人均流通股9676股，较上期减少 53.05%。2025年1月-9月，向日葵实现营业收入2.00亿元，同比减少12.09%；归母净利润1 ...

12月24日，荣昌生物盘中上涨2.07%，截至09:39，报81.76元/股，成交5859.50万元，换手率0.45%，总 市值460.89亿元。 资金流向方面，主力资金净流出104.98万元，大单买入527.21万元，占比9.00%，卖出632.19万元，占比 10.79%。 荣昌生物今年以来股价涨171.54%，近5个交易日跌0.17%，近20日跌11.37%，近60日跌20.83%。 今年以来荣昌生物已经4次登上龙虎榜，最近一次登上龙虎榜为6月26日，当日龙虎榜净买入-1.37亿 元；买入总计2.35亿元 ，占总成交额比15.86%；卖出总计3.72亿元 ，占总成交额比25.12%。 截至9月30日，荣昌生物股东户数1.53万，较上期增加18.33%；人均流通股10639股，较上期减少 15.54%。2025年1月-9月，荣昌生物实现营业收入17.20亿元，同比增长42.27%；归母净利润-5.51亿元， 同比增长48.60%。 资料显示，荣昌生物制药(烟台)股份有限公司位于中国(山东)自由贸易试验区烟台片区烟台开发区北京 中路58号，成立日期2008年7月4日，上市日期2022年3月31日，公司主营业 ...

科创债5月以来发行额度 科创债募集资金用途 张大伟 制图 ◎记者 孙忠 2025年，债市"科技板"亮相，截至目前科创债规模已突破1.7万亿元。 今年全国两会期间，中国人民银行表示将推动债券市场"科技板"建设。5月7日，中国人民银行、中国证 监会联合发布《关于支持发行科技创新债券有关事宜的公告》，正式宣告债市"科技板"落地，科创债也 迎来快速发展的新时代。 市场人士表示，这拓宽了科技创新企业融资渠道，引导债券市场资金投早、投小、投长期、投硬科技， 激发科技创新动力和市场活力，助力培育新质生产力。 2025年，科创债不仅规模大幅增加，同时生态建设也渐趋完善，不仅有科创债ETF横空出世，提升市场 流动性和参与度，同时信用风险缓释工具及信用违约互换等风险管理工具也不断创新，更好地为投资者 保驾护航。 规模突破1.7万亿元 2025年，科创债成为支持科技创新型企业的一个重要品种。 在中国人民银行、中国证监会发布公告后，交易商协会和沪深北三大交易所发布科创债相关业务细则， 市场反响热烈。科创债呈现快速扩容的局面。 5月，科创债发行规模达到3492亿元，符合条件的金融机构、创投公司、科创公司等纷纷试水。此后， 科创债发行规 ...

Core Viewpoint - Dongtu Technology (300353.SZ) aims to leverage the resources and investment operations of professional investment institutions to expand its industrial layout and incubate quality collaborative projects through participation in the Sichuan Chengde High-tech Innovation Equity Investment Fund initiated by Beijing Yamei [1] Group 1 - The total fundraising scale of the Chengde Fund is 620 million yuan, with Dongtu Technology planning to contribute 108.5 million yuan, accounting for 17.5% of the total investment [1] - The Chengde Fund will focus on strategic emerging industries with an emphasis on international cooperation, particularly in the fields of medical technology, digital economy, artificial intelligence, and intelligent manufacturing [1] - The fund will invest at least 50% in the biomedicine and health technology sectors, while allocating no less than 40% to artificial intelligence, digital technology, and industrial intelligence [1]

Core Insights - The Yangtze River Delta (YRD) is entering a period of "fourfold opportunities" as it approaches the 14th Five-Year Plan, emphasizing the need for collaborative innovation ecosystems, institutional openness, infrastructure improvement, and innovative regional cooperation mechanisms [1][3]. Group 1: Fourfold Opportunities - The YRD is experiencing a convergence of national strategic initiatives, industrial cluster development, rich scientific and technological resources, and accelerated open economy growth [3]. - The region's strategic position is increasingly prominent as it leads China's economic development while balancing regional growth [1]. Group 2: Collaborative Innovation - There is a strong emphasis on leveraging the YRD's technological innovation resources to establish cross-regional collaborative innovation mechanisms [3]. - Initiatives include the joint development of major scientific infrastructure and a collaborative plan focusing on key sectors such as integrated circuits, artificial intelligence, and biomedicine [3][4]. Group 3: Institutional Openness - The YRD provinces and cities are encouraged to pioneer institutional openness in areas such as rules, regulations, management, and standards, aligning with international high-standard trade rules [4][5]. - Efforts to eliminate hidden barriers to the free flow of resources are essential, particularly in technology transactions and talent evaluation [5]. Group 4: Infrastructure Development - Infrastructure connectivity is identified as a foundational element for YRD integration, with a call to accelerate the construction of a world-class port and airport network [5]. - The development of digital infrastructure and collaborative platforms for computing power is also highlighted as a priority [5]. Group 5: Shared Benefits and Cost Mechanisms - The establishment of various forms of benefit-sharing and cost-sharing mechanisms is recommended to promote collaborative advantages in the YRD [5]. - The success of collaborative industrial funds should be leveraged to create a metropolitan area industrial innovation fund [5].

Core Insights - The Central Economic Work Conference summarized the economic work for 2025 and analyzed the current economic situation, setting the stage for 2026 economic work [1][4][17] Economic Performance - In the first three quarters of 2025, China's GDP grew by 5.2% year-on-year, with the total economic output expected to reach around 140 trillion yuan [3][5] - The economic development goals for the year are on track to be achieved, reflecting a resilient and vibrant economy [4][6] Key Areas of Focus - The conference highlighted five key areas for economic work: 1. Overall economic stability and progress, with major indicators meeting expectations [5] 2. Continuous advancement in modern industrial system construction, with significant achievements in technology and innovation [5] 3. Progress in reform and opening up, with a focus on building a unified national market [5] 4. Positive developments in risk mitigation in key areas, including local government debt management [5] 5. Strengthened social welfare measures, including childcare subsidies and free education [5] Policy Directions for 2026 - The conference outlined the policy direction for 2026, emphasizing stability and quality improvement, with a focus on integrating existing and new policies [17][19] - A more proactive fiscal policy will be implemented, maintaining necessary fiscal deficits and ensuring sustainable finances [20][21] - An appropriately loose monetary policy will be adopted to support economic stability and reasonable price recovery [22] Eight Key Tasks for "15th Five-Year Plan" - The conference identified eight key tasks to ensure a strong start for the "15th Five-Year Plan": 1. Focus on domestic demand and build a strong domestic market [26] 2. Accelerate innovation-driven development [26] 3. Enhance high-quality development dynamics through reform [26] 4. Promote win-win cooperation in international trade [26] 5. Foster coordinated development between urban and rural areas [26] 6. Lead with carbon neutrality initiatives for green transformation [26] 7. Prioritize people's livelihoods and address practical issues [26] 8. Mitigate risks in key areas effectively [26][32]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Medisi, indicating a stock price increase of 92.38% year-to-date and a market capitalization of 7.798 billion yuan [2] - Medisi's stock price reached 58.04 yuan per share with a trading volume of 81.93 million yuan and a turnover rate of 1.06% as of December 23 [1] - The company has seen a net inflow of main funds amounting to 1.4455 million yuan, with significant buying and selling activities recorded [1] Group 2 - Medisi's business primarily involves providing comprehensive new drug research services to pharmaceutical companies and other new drug research institutions, with revenue composition being 50.34% from preclinical research and 49.64% from drug discovery and pharmaceutical research [2] - As of September 30, the number of shareholders increased by 27.83% to 16,500, while the average circulating shares per person decreased by 21.96% to 8,149 shares [2] - For the period from January to September 2025, Medisi achieved an operating income of 843 million yuan, reflecting a year-on-year growth of 5.14%, while the net profit attributable to the parent company was -29.6849 million yuan, showing a significant year-on-year increase of 76.93% [2] Group 3 - Medisi has distributed a total of 158 million yuan in dividends since its A-share listing, with cumulative distributions of 33.9365 million yuan over the past three years [3]

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.01% on December 23, with a current price of 26.88 yuan per share and a total market capitalization of 12.843 billion yuan. The company has seen significant fluctuations in its stock price throughout the year, with a year-to-date increase of 262.75% but a recent decline over the past 20 and 60 days [1]. Financial Performance - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, representing a year-on-year decrease of 30.82%. The net profit attributable to the parent company was -30.6895 million yuan, a decline of 227.71% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Shuyou Shen was 46,500, an increase of 46.97% from the previous period. The average number of circulating shares per shareholder was 9,745, which decreased by 31.98% [2]. Dividend Distribution - Since its A-share listing, Shuyou Shen has distributed a total of 771 million yuan in dividends. However, there have been no dividend distributions in the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, Xingshan He Run Mixed A ranked as the third-largest shareholder with 12.2691 million shares, a decrease of 3.4519 million shares from the previous period. Xingshan He Yi Mixed A ranked fifth with 9.3396 million shares, an increase of 3.3875 million shares [3].

百奥泰所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：生物医药、创新药、 抗癌治癌、抗癌药物、小盘等。 截至9月30日，百奥泰股东户数9397.00，较上期减少0.89%；人均流通股44065股，较上期增加0.89%。 2025年1月-9月，百奥泰实现营业收入6.84亿元，同比增长17.57%；归母净利润-2.24亿元，同比增长 38.72%。 机构持仓方面，截止2025年9月30日，百奥泰十大流通股东中，香港中央结算有限公司位居第十大流通 股东，持股602.47万股，为新进股东。 12月23日，百奥泰盘中上涨2.03%，截至09:44，报23.63元/股，成交816.40万元，换手率0.08%，总市值 97.85亿元。 资金流向方面，主力资金净流入79.45万元，大单买入123.19万元，占比15.09%，卖出43.75万元，占比 5.36%。 百奥泰今年以来股价涨21.93%，近5个交易日涨3.50%，近20日跌5.48%，近60日跌21.13%。 资料显示，百奥泰生物制药股份有限公司位于广东省广州市国际生物岛螺旋二路18号，成立日期2003年 7月28日，上市日期2020年2月21日 ...